INSMED IncINSM
What INSMED Inc does.
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.
Our two commercial products, ARIKAYCE ® and BRINSUPRI ® , are both part of the Respiratory therapeutic area. ARIKAYCE is approved in the US as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE Liposomal for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which we refer to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $164.4M | $188.5M | $245.4M | $305.2M | $363.7M | $606.4M |
| Net income | -$294.1M | -$434.7M | -$481.5M | -$749.6M | -$913.8M | -$1.3B |
| Free cash flow | -$225.6M | -$370.6M | -$410.3M | -$549.5M | -$705.8M | -$967.6M |
More on INSM.
- INSMED Inc summary
- INSMED Inc financial statements
- INSMED Inc key metrics
- INSMED Inc health scores and style box
- INSMED Inc earnings
- INSMED Inc dividends
- INSMED Inc valuation
- INSMED Inc ownership and insiders
- INSMED Inc peers
Figures from INSMED Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.